BidaskClub lowered shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a sell rating to a strong sell rating in a research note published on Thursday morning.

Several other analysts have also issued reports on IRWD. Zacks Investment Research lowered Ironwood Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, January 9th. ValuEngine lowered Ironwood Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, October 2nd. Bank of America lowered Ironwood Pharmaceuticals from a buy rating to an underperform rating and dropped their price objective for the company from $20.00 to $15.00 in a research note on Friday, January 5th. Morgan Stanley reiterated a hold rating on shares of Ironwood Pharmaceuticals in a research note on Monday, December 4th. Finally, Mizuho lowered Ironwood Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for the stock from $20.00 to $16.00 in a research note on Wednesday, December 6th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $17.56.

Ironwood Pharmaceuticals (NASDAQ IRWD) traded up $0.38 during trading hours on Thursday, reaching $15.38. The company’s stock had a trading volume of 1,260,000 shares, compared to its average volume of 1,290,000. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31. The company has a market capitalization of $2,360.00, a price-to-earnings ratio of -16.02 and a beta of 1.45. Ironwood Pharmaceuticals has a 12-month low of $13.43 and a 12-month high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.07. The firm had revenue of $86.80 million for the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The business’s revenue for the quarter was up 31.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.18) earnings per share. equities research analysts forecast that Ironwood Pharmaceuticals will post -1.11 earnings per share for the current fiscal year.

In related news, CEO Peter M. Hecht sold 113,405 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the sale, the chief executive officer now owns 4,696,917 shares of the company’s stock, valued at $71,017,385.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 115,769 shares of company stock worth $1,752,491. 7.63% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Ironwood Pharmaceuticals by 2.4% during the second quarter. Vanguard Group Inc. now owns 10,761,867 shares of the biotechnology company’s stock worth $203,184,000 after buying an additional 256,406 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Ironwood Pharmaceuticals during the second quarter worth approximately $150,460,000. State Street Corp grew its position in Ironwood Pharmaceuticals by 13.7% during the second quarter. State Street Corp now owns 4,530,267 shares of the biotechnology company’s stock worth $85,533,000 after buying an additional 545,464 shares in the last quarter. EcoR1 Capital LLC grew its position in Ironwood Pharmaceuticals by 29.2% during the second quarter. EcoR1 Capital LLC now owns 3,753,635 shares of the biotechnology company’s stock worth $70,869,000 after buying an additional 848,120 shares in the last quarter. Finally, Pictet Asset Management Ltd. grew its position in Ironwood Pharmaceuticals by 37.5% during the third quarter. Pictet Asset Management Ltd. now owns 2,622,507 shares of the biotechnology company’s stock worth $41,357,000 after buying an additional 715,147 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “Ironwood Pharmaceuticals (IRWD) Lowered to “Strong Sell” at BidaskClub” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/20/ironwood-pharmaceuticals-irwd-lowered-to-strong-sell-at-bidaskclub.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.